T3 Companies’s Cocrystal Pharma COCP Stock Holding History

T3 Companies’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-51,500	Closed	-$52K	–	188
2026 Q1	$52K	Sell	51,500 -800	-2%	-$825	0.07%	94
2025 Q4	$51.2K	Buy	+52,300	New	+$55.4K	0.06%	130

Other funds holding COCP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

T3 Companies's COCP Position: Q2 2026 in Review

T3 Companies sold out of Cocrystal Pharma (COCP) in Q2 2026, closing a stake of 51,500 shares — an estimated $52K sold.

T3 Companies first reported a position in COCP in Q4 2025 and held it in 2 quarters. The position peaked at $52K in Q1 2026. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

T3 Companies reported no remaining Cocrystal Pharma position as of Q2 2026 after selling out during the quarter.
T3 Companies sold 51,500 Cocrystal Pharma shares in Q2 2026, an estimated $52K.
T3 Companies first reported a position in Cocrystal Pharma in Q4 2025 and held it in 2 quarters.
T3 Companies's Cocrystal Pharma position peaked at $52K in Q1 2026.
27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.